Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.
Drug Commission of German Pharmacists (AMK), Heidestraße 7, 10557, Berlin, Germany.
Clin Res Cardiol. 2024 Aug;113(8):1103-1116. doi: 10.1007/s00392-023-02230-3. Epub 2023 May 20.
Primary medication non-adherence describes the situation when a first prescription for a new medication is never filled. Primary non-adherence is an important, yet understudied aspect of reduced effectiveness of pharmacotherapy. This review summarizes the frequency, impact, reasons, predictors, and interventions regarding primary non-adherence to cardiovascular/cardiometabolic drugs. The current literature reveals a high prevalence of primary non-adherence. The individual risk of primary non-adherence is determined on multiple factors, e.g., primary non-adherence of lipid-lowering drugs is higher compared to antihypertensive medications. However, the overall rate of primary non-adherence is > 10%. Additionally, this review identifies specific areas for research to better understand why patients forgo evidence-based beneficial pharmacotherapy and to explore targeted interventions. At the same time, measures to reduce primary non-adherence-once proven to be effective-may represent an important new opportunity to reduce cardiovascular diseases.
主要药物不依从性描述的是一种新处方药物从未被配药的情况。主要不依从性是药物治疗效果降低的一个重要但研究不足的方面。这篇综述总结了心血管/心脏代谢药物主要不依从性的频率、影响、原因、预测因素和干预措施。目前的文献显示主要不依从性的发生率很高。个体发生主要不依从性的风险由多种因素决定,例如,与降压药物相比,降脂药物的主要不依从性更高。然而,总体主要不依从性的比率>10%。此外,本综述确定了具体的研究领域,以更好地了解为什么患者会放弃基于证据的有益药物治疗,并探索有针对性的干预措施。同时,一旦证明减少主要不依从性是有效的措施,可能代表减少心血管疾病的一个重要新机会。